Clinical preferences for DME in Japan
Sugimoto, Masahiko Mie University
Tsukitome, Hideyuki Mie University
Okamoto, Fumiki University of Tsukuba
Oshika, Tetsuro University of Tsukuba
Ueda, Tetsuo Nara Medical University
Niki, Masanori Tokushima University Tokushima University Educator and Researcher Directory
Mitamura, Yoshinori Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Ishikawa, Hiroto Hyogo College of Medicine
Gomi, Fumi Hyogo College of Medicine
Kitano, Shigehiko Tokyo Women’s Medical University
Noma, Hidetaka Tokyo Medical University
Shimura, Masahiko Tokyo Medical University
Sonoda, Shozo Kagoshima University
Sawada, Osamu Shiga University of Medical Science
Ohji, Masahito Shiga University of Medical Science
Harimoto, Kozo National Defense Medical College
Takeuchi, Masaru National Defense Medical College
Takamura, Yoshihiro University of Fukui
Kondo, Mineo Mie University
Sakamoto, Taiji Kagoshima University
Clinical practice pattern
Diabetic macular edema
Vascular endothelial growth factor
Aims/Introduction: To determine the current clinical preferences of anti‐vascular endothelial growth factor (VEGF) treatment protocols for diabetic macular edema (DME) in Japan.
Materials and Methods: This was a descriptive cross‐sectional study. Answers to a questionnaire consisting of 16 questions were obtained from 176 of 278 (63.3%) surveyed ophthalmologists.
Results: The results showed that 81.2% preferred intravitreal injections of anti‐VEGF antibodies as the first‐line therapy. The most important indicators for beginning anti‐VEGF therapy were: the best‐corrected visual acuity in 44.3% and the retinal thickness in 30.7%. In the loading phase, 53.4% preferred a single injection, and in the maintenance phase, 75.0% preferred the pro re nata regimen. Financial limitation (85.8%) was reported as the most important difficulty in the treatment. For combination therapy with anti‐VEGF treatment, panretinal photocoagulation, focal photocoagulations and a sub‐Tenon steroid injection were preferred. The contraindications for anti‐VEGF therapy were: prior cerebral infarction (72.7%). Regarding the use of both approved anti‐VEGF agents in Japan, ranibizumab and aflibercept, 39.8% doctors used them appropriately.
Conclusions: Our results present the current clinical preferences of anti‐VEGF treatment for DME in Japan. The best‐corrected visual acuity and the retinal thickness are important indicators to institute this therapy. The majority of the ophthalmologists use anti‐VEGF treatment as first‐line therapy and prefer the 1 + pro re nata regimen.
Journal of Diabetes Investigation
Asian Association for the Study of Diabetes|John Wiley & Sons
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License(https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
|DOI (Published Version)|
|URL ( Publisher's Version )|
jdi_10_2_475.pdf 375 KB